The BCL-2 family of proteins regulates apoptosis by controlling mitochondrial permeability and release of cytochrome C. BCL-2 is an anti-apoptotic protein that resides in the outer mitochondrial wall and inhibits the release of cytochrome C. Over-expression of BCL-2 has been shown to promote cell survival by suppressing apoptosis. It has been documented that BCL-2 becomes deregulated in tumor cells as a result of translocation into the immunoglobulin heavy-chain locus and is therefore activated in B-cell malignancies. BCL-2 antibody is useful in the differentiation of follicular lymphoma from reactive follicular proliferation (Bcl-2 negative). In addition, BCL-2 expression has been shown to be correlated with disease prognosis in breast cancer, prostate cancer, ovarian cancer, endometrial cancer, and colon cancer.
The BCL-2 family of proteins regulates apoptosis by controlling mitochondrial permeability and release of cytochrome C. BCL-2 is an anti-apoptotic protein that resides in the outer mitochondrial wall and inhibits the release of cytochrome C. Over-expression of BCL-2 has been shown to promote cell survival by suppressing apoptosis. It has been documented that BCL-2 becomes deregulated in tumor cells as a result of translocation into the immunoglobulin heavy-chain locus and is therefore activated in B-cell malignancies. BCL-2 antibody is useful in the differentiation of follicular lymphoma from reactive follicular proliferation (Bcl-2 negative). In addition, BCL-2 expression has been shown to be correlated with disease prognosis in breast cancer, prostate cancer, ovarian cancer, endometrial cancer, and colon cancer.